Evidence map›Paper›PMID 28374920›Full record

ArticleJournal of clinical laboratory analysis2018

The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Marco Benati, Martina Montagnana, Elisa Danese, Elisa Paviati, Silvia Giudici, Orazio Ruzzenente, Massimo Franchi, Giuseppe Lippi

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03459976 (HE4 is a Beneficial Biomarker in Endometrial Cancer), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03459976 unknown statusnot on this map

HE4 is a Beneficial Biomarker in Endometrial Cancer

TypeobservationalSponsorAin Shams UniversityRan2017 to 2019Enrolled87ConditionsEndometrial CancerArmsevaluate serum level HE4 in endometrial cancer
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marco BenatiDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.
Martina MontagnanaDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0001-8999-0001
Elisa DaneseDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.
Elisa PaviatiDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.
Silvia GiudiciDepartment of Surgery, Obstetrics and Gynaecology Section, University of Verona, Verona, Italy.
Orazio RuzzenenteDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.
Massimo FranchiDepartment of Surgery, Obstetrics and Gynaecology Section, University of Verona, Verona, Italy.
Giuseppe LippiDepartment of Neurological, Biomedical and Movement Sciences, Clinical Biochemistry Section, University of Verona, Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe non-invasive diagnostic approach for early detection of endometrial cancer (EC) remains limited. To date, human epididymis protein 4 (HE4) has been intensively studied but its diagnostic is controversial in EC. DJ-1 is an oncoprotein secreted by cancer cells, recently identified as a potential diagnostic biomarker for breast cancer, melanoma, and pancreatic cancer. The aim of this study was to compare the diagnostic performances of DJ-1 and HE4 measured in EC patients and healthy controls (HC).

methodsForty-five patients (63.9±12.0 years) with EC and 29 (63.2±13.3 years) HC were enrolled. Serum concentrations of DJ-1 and HE4 were measured using ELISA kits developed by R&D (Minneapolis, USA) and Fujirebio Diagnostic (Malvern, PA, USA), respectively. Differences between EC patients and HC were assessed by Mann-Whitney test and associations were tested by Spearman's correlation. The diagnostic performance was assessed using receiver operating characteristics (ROC) curves analysis.

resultsSerum DJ-1 concentrations were found to be higher in EC patients than in HC (9533.6 vs 1988.5 pg/mL; P<.0001). The area under the ROC curve (ROC-AUC) was 0.95 (P<.0001). At the cut-off of 3654 pg/mL, the sensitivity and specificity were 0.89 and 0.90, respectively. HE4 serum levels were higher in EC patients than in HC (75.3 vs 56.2 pmol/L; P=.019), with an AUC of 0.66 (P=.020). The AUC obtained by the combination of the two markers resulted 0.96 (P<.0001).

conclusionThese results suggest that increased serum DJ-1 levels are associated with EC and that this biomarker may be potentially useful for diagnosing EC.

Indexed as

AgedArea Under CurveBiomarkers, TumorCase-Control StudiesEndometrial NeoplasmsFemaleHumansMiddle AgedProtein Deglycase DJ-1ProteinsWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorPARK7 protein, humanProtein Deglycase DJ-1ProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanDJ-1endometrial cancerHE4PARK7

Identifiers

PMID28374920
PMCPMC6817134
OpenAlexW2604613672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.